Sign in

pgrivasmdphd.bsky.social

@pgrivasmdphd.bsky.social
239 followers 45 following 25 posts
PostsRepliesMedia
pgrivasmdphd.bsky.social @pgrivasmdphd.bsky.social · 02/04/2025
1/ Best practices for 2L+ tx #MetastaticUrothelialCarcinoma 🧵 w🌟 @tiansterzhangmd.bsky.social & me ...assuming EV+P 1L ✅FGFR3 alts: THOR/erda 🎯Trop-2: sacituzumab govitecan 🏁HER2 IHC 3+: T-DXd Support by edu grants: Astellas, Gilead Sci, Merck, Seagen #CME from @bonumce.bsky.social ℹ️👇
111
Reposted by @pgrivasmdphd.bsky.social
Tian Zhang, MD @tiansterzhangmd.bsky.social · 24/01/2025
This GU oncology family — wonderful first #AUC3 consensus conference! @drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social
083
Reposted by @pgrivasmdphd.bsky.social
Jame Abraham, MD, FACP @jameabraham.bsky.social · 31/01/2025
Expanded indication for TDXd!
062
Reposted by @pgrivasmdphd.bsky.social
The OncoAlert Network 🚨 @oncoalert.bsky.social · 01/01/2025
Happy New Year from OncoAlert @jrgralow.bsky.social @elisabettabonzano.bsky.social @stolaney1.bsky.social @stoverlab.bsky.social @pgrivasmdphd.bsky.social @axelmerseburger.bsky.social @drnataliagandur.bsky.social @biagioricciutimd.bsky.social @fernandoonco.bsky.social
162
Reposted by @pgrivasmdphd.bsky.social
Tian Zhang, MD @tiansterzhangmd.bsky.social · 23/01/2025
Awesome panel moderated by #MontyPal #BradMcGregor for non clear cell #Kidneycancer. Histology matters! And so do molecular markers! #AUC3 @drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social @erplimackmd.bsky.social
041
Reposted by @pgrivasmdphd.bsky.social
Yüksel Ürün @yukselurun.bsky.social · 09/12/2024
Redefining first-line options for advanced urothelial carcinoma! Insights on platinum chemotherapy, immunotherapy combos, and patient-tailored strategies. @tiansterzhangmd.bsky.social @oncoalert.bsky.social @oncbrothers.bsky.social #Oncology #BladderCancer
063
Reposted by @pgrivasmdphd.bsky.social
Todd Morgan, MD @wandering-gu.bsky.social · 10/12/2024
Huge kudos to the NCCN for officially incorporating prostate cancer into the Genetic/Familial High-Risk Assessment Guidelines. We've come a long way!
0174
Reposted by @pgrivasmdphd.bsky.social
Tian Zhang, MD @tiansterzhangmd.bsky.social · 26/12/2024
This Christmas and every year I remember my current and past patients with ornaments on our tree. Have been fortunate to care for thousands in my ten year career in oncology. Hope to help thousands more in the years to come. 🎄🕯️
082
Reposted by @pgrivasmdphd.bsky.social
Tian Zhang, MD @tiansterzhangmd.bsky.social · 23/01/2025
021
Reposted by @pgrivasmdphd.bsky.social
Tian Zhang, MD @tiansterzhangmd.bsky.social · 23/01/2025
Launching #AUC3 in Miami, consensus across kidney and bladder cancers. From small steps to significant scientific advances that change our patients’ lives. @drchoueiri.bsky.social #MontyPal #RanaMcKay #JonathanRosenberg
143
Reposted by @pgrivasmdphd.bsky.social
Tian Zhang, MD @tiansterzhangmd.bsky.social · 23/01/2025
#BrianShuch kicks us off, local #kidneycancer heterogeneous - guppies, goldfish and sharks! Integrating staging & biomarkers to help us evaluate risk and prognosis. #AUC3
041
Reposted by @pgrivasmdphd.bsky.social
Tian Zhang, MD @tiansterzhangmd.bsky.social · 23/01/2025
Drs. #NaomiHaas #HansHammers debate locally advanced #kidneycancer and use of periop immunotherapy. Grading, staging, and prediction of risk/benefit leads to rigorous shared decision making with our patients. @drchoueiri.bsky.social #AUC3
052
Reposted by @pgrivasmdphd.bsky.social
Tian Zhang, MD @tiansterzhangmd.bsky.social · 23/01/2025
#BrianRini & #MikeAtkins debate refractory #kidneycancer management after IO front line or adjuvant PD1 inhibitor. Do we rechallenge? Yes likely after a certain time point (6 vs 12 months debated). #AUC3
042
Reposted by @pgrivasmdphd.bsky.social
Alfonso De Stefano @adestefano.bsky.social · 21/12/2024
Great milestone 🎯🥇 for #mCRC treatment #GIonc #OncSky based on the last update clinicaltrials.gov/study/NCT046... FDA grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer www.fda.gov/drugs/resour...
clinicaltrials.gov
ClinicalTrials.gov
022
Reposted by @pgrivasmdphd.bsky.social
Aakash Desai @adesaimd.bsky.social · 21/12/2024
🔍 Does AI reduce #clinician workload? @NEJM study on @NuanceDragon DAX Copilot, an AI-powered documentation tool, found minimal impact on EHR efficiency & financial metrics❗️ 💡AI tools need to be developed in comjuction with 🩺🥼🧑‍⚕️ not in silos #AIinMedicine #LLMs @oncoalert.bsky.social
375
pgrivasmdphd.bsky.social @pgrivasmdphd.bsky.social · 23/12/2024
Congratulations @n8pennell.bsky.social and all elected members @ascocancer.bsky.social
020
Reposted by @pgrivasmdphd.bsky.social
Yvonne Diaz @yvonnediaz.bsky.social · 22/12/2024
“Why are we listening to men & not women?” asks Dr @narjustflorezmd.bsky.social of @florezlab.bsky.social This question & the increase in #lungcancer diagnoses among younger women vs men are the genesis for the #HearHer campaign. Read more & help us change this👇 healio.com/news/hematolog… #LCSM
094
Reposted by @pgrivasmdphd.bsky.social
Jennifer A. Marks, MD @jennifermarksmd.bsky.social · 22/12/2024
Interesting article studying oncologist’s decision-making from a psychosocial perspective: #Oncologists exposed to scenarios of a “nice” or “demanding” pt were associated with less recommendations of chemotherapy near the #EOL . #heme/onc #lcsm #lcam #oncsky #medsky doi.org/10.1093/onco...
doi.org
Patients’ psychosocial attributes and aggressiveness of cancer treatments near the end of life
AbstractBackground. While the use of chemotherapy near the end of life (EOL) has been identified as a relevant criterion for assessing quality of cancer ca
0104
Reposted by @pgrivasmdphd.bsky.social
Eleonora Teplinsky, MD @drteplinsky.bsky.social · 22/12/2024
083
Reposted by @pgrivasmdphd.bsky.social
Narjust Florez, MD, FASCO @narjustflorezmd.bsky.social · 22/12/2024
Key takeaways: •The #HearHer campaign focuses on gender disparities in lung cancer diagnosis and clinical trial enrollment. •Clinicians should take women’s concerns seriously and make use of imaging for early detection. Article here: www.healio.com/news/hematol...
073
Reposted by @pgrivasmdphd.bsky.social
Tatiana Prowell, MD @tmprowell.bsky.social · 08/12/2024
🧵 Real world effectiveness study using #EHR from 20 health systems: #COVID19 vaccination ⬇️ risk of #longCOVID in kids/adolescents during Delta & Omicron waves. Mediation analysis suggests effectiveness is indirect, via ⬇️ the risk of #SARSCoV2 infection. #MedTwitter #MedSky
2358
Reposted by @pgrivasmdphd.bsky.social
Tatiana Prowell, MD @tmprowell.bsky.social · 08/12/2024
Link to the original study examining real world effectiveness of #COVID19 vaccination in reducing risk of #LongCovid in kids & adolescents here: www.thelancet.com/action/showP.... #MedSky #IDSky #Pediatrics #GetVaccinated
thelancet.com
1103
pgrivasmdphd.bsky.social @pgrivasmdphd.bsky.social · 06/12/2024
Stayed active during 17-hour flight from SEA->Singapore :-) Looking forward to present TROPiCS04 phase 3 trial data at #ESMOASIA on Dec 7 ~10am local time discussed by Dr. Friedlander @oncoalert.bsky.social @achoud72.bsky.social @erplimackmd.bsky.social @valdesan.bsky.social @fredhutch.bsky.social
172
Reposted by @pgrivasmdphd.bsky.social
The OncoAlert Network 🚨 @oncoalert.bsky.social · 02/12/2024
Thank you Mirrors of Medicine & dear Colleagues #PROSCA24 #BLADDR24 & #RENALC24 FINAL STATS with OVER 21 million impression on X SHOUT OUT TO Our Ambassadors Specially @drnataliagandur.bsky.social @barbaramelao.bsky.social @pgrivasmdphd.bsky.social @achoud72.bsky.social
064
pgrivasmdphd.bsky.social @pgrivasmdphd.bsky.social · 02/12/2024
As we return from Thanksgiving Holidays we are grateful for everyone’s hard work & @ASCO mission to support providers & patients! Would like to remind active members to participate in @ASCO election-stellar candidates across all categories-Deadline: Dec 3rd 3pm EST society.asco.org/about-asco/a...
society.asco.org
ASCO Election
ASCO Election
041
Reposted by @pgrivasmdphd.bsky.social
Darcy Burbage, DNP, RN, AOCN @darcyburbage.bsky.social · 21/11/2024
“The effectiveness of telehealth in delivering psychosocial, nutritional, and physical activity support highlights its potential to improve patient outcomes and overcome barriers to care” @pallonccop.bsky.social #oncsky ascopubs.org/doi/10.1200/...
ascopubs.org
Enhancing Cancer Supportive Care: Integrating Psychosocial Support, Nutrition, and Physical Activity Using Telehealth Solutions | JCO Global Oncology
This review explores current guidelines for integrating psychosocial support, nutrition, and physical activity into cancer care and examines the resources available to deliver comprehensive care effec...
0189
Reposted by @pgrivasmdphd.bsky.social
Bárbara Melão @barbaramelao.bsky.social · 29/11/2024
#PROSCA24 ✨PSMA is the imaging choice in BCR ✨impact on clinical management ~60% ✨PPV 85-90% ✨different PSMA tracers with different detection rate ✨PROMISE registry to build monogram to predict survival: in BCR setting the nomogram had a strong correlation with survival ‼️for MDT: use PSMA11
053
Reposted by @pgrivasmdphd.bsky.social
Jarushka Naidoo @drjnaidoo.bsky.social · 29/11/2024
Impact of cycle 1 irAEs on ICI outcomes: - 683pts from SWOG DART trial - g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001 - g3+ irAEs = ⬇️OS HR  1.41 p= .025 - g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002 Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social academic.oup.com/jnci/advance...
academic.oup.com
First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors
AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate
02715
Reposted by @pgrivasmdphd.bsky.social
Daniel Stover, MD, FASCO @stoverlab.bsky.social · 30/11/2024
Do systemic responses to ICI (eg irAEs) associate w outcomes? Nice use of existing basket studies by @pateloncology.bsky.social @eladsharonmd.bsky.social Razelle Kurzrock et al
1268
Reposted by @pgrivasmdphd.bsky.social
The OncoAlert Network 🚨 @oncoalert.bsky.social · 30/11/2024
Thank you Mirrors of Medicine & dear Colleagues #PROSCA24 #BLADDR24 & #RENALC24 have just concluded with OVER 20 million impression on X SHOUT OUT TO Our Ambassadors Specially @drnataliagandur.bsky.social @barbaramelao.bsky.social @pgrivasmdphd.bsky.social @achoud72.bsky.social
084
Reposted by @pgrivasmdphd.bsky.social
The OncoAlert Network 🚨 @oncoalert.bsky.social · 30/11/2024
Join Drs. Gillessen, Omlin, Castro, Zilli, Tombel & Turco as they discuss Advanced Prostate Cancer Consensus Conference 2024, presentation at #PROSCA24 #ProstateCancer buff.ly/3B5902t @drnataliagandur.bsky.social @barbaramelao.bsky.social @achoud72.bsky.social @pgrivasmdphd.bsky.social
buff.ly
Highlights from APCCC 2024 in Prostate Cancer Final day of #PROSCA24
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where h...
0105
Reposted by @pgrivasmdphd.bsky.social
Tatiana Prowell, MD @tmprowell.bsky.social · 29/11/2024
Good job Team #DiagnoseAndTreats! Keep up the donations, #OncSky, #RadSky, #PathSky, #RadOnc, #OncoAlert! We are your multi-d cancer fighting team for #HCWvsHunger 2024!
0152
Reposted by @pgrivasmdphd.bsky.social
Narjust Florez, MD, FASCO @narjustflorezmd.bsky.social · 28/11/2024
#HearHer
0103
Reposted by @pgrivasmdphd.bsky.social
Vivek Subbiah, MD @viveksubbiah.bsky.social · 20/11/2024
⭐️Pancreatic Cancer Surge May Be Less Worrisome Than It Seemed A rise in the disease in younger people was not followed by an increase in deaths, a study found, and might be a sign of overdiagnosis @nytimes.com www.nytimes.com/2024/11/18/h...
nytimes.com
Pancreatic Cancer Surge May Be Less Worrisome Than It Seemed
A rise in the disease in younger people was not followed by an increase in deaths, a study found, and might be a sign of overdiagnosis.
0134
Reposted by @pgrivasmdphd.bsky.social
Vivek Subbiah, MD @viveksubbiah.bsky.social · 22/11/2024
🥁🥁🥁Super honored to host a JAMA Oncology podcast with the one & only giant of leukemia, Dr. Hagop Kantarjian 🎙️ Listen to a tour de force of all therapies in CML. ⭐️CML is the poster child for precision oncology Link: edhub.ama-assn.org/jn-learning/...
0192
Reposted by @pgrivasmdphd.bsky.social
Vivek Subbiah, MD @viveksubbiah.bsky.social · 24/11/2024
⭐️Development and phenotype of regulatory T cells This picture is worth 100 K words! Link to pdf: www.stemcell.com/media/files/...
03612
Reposted by @pgrivasmdphd.bsky.social
Vivek Subbiah, MD @viveksubbiah.bsky.social · 26/11/2024
⭐️Nice review @theaacr.bsky.social journal Cancer Discovery 👉🏼The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development @ptarantinomd.bsky.social bit.ly/3YZn7OK
bit.ly
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Abstract. Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clin...
1208
Reposted by @pgrivasmdphd.bsky.social
Vivek Subbiah, MD @viveksubbiah.bsky.social · 28/11/2024
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer www.nejm.org/doi/full/10....
nejm.org
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer | NEJM
Patients with microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted therapi...
03015
Reposted by @pgrivasmdphd.bsky.social
Vivek Subbiah, MD @viveksubbiah.bsky.social · 28/11/2024
🍁Grateful hearts, joyful gatherings, and one filled with love and laughter. Wishing you all a blessed and bountiful Thanksgiving. 🍁🦃 #Thankful #Gratitude #HappyThanksgiving   #thanksgiving2024 #Thanksgiving  #Thanksgiving24 #oncsky #medsky
0142
Reposted by @pgrivasmdphd.bsky.social
Tatiana Prowell, MD @tmprowell.bsky.social · 29/11/2024
Friends, help us feed folks via #HCWvsHunger! Donate to any local food bank (find one buff.ly/2EhMZ28) or hunger org, 📸 your receipt, & log it for your fave #MedTwitter or #MedSky team at HCWvsHunger.org by 12/3. FAQs there too!
buff.ly
Find Your Local Food Bank | Feeding America
Find the Feeding America member food bank nearest you. Over 200 member food banks can connect you with free food, food pantries, soup kitchens, and mobile pantries in your community.
02718
Reposted by @pgrivasmdphd.bsky.social
Vivek Subbiah, MD @viveksubbiah.bsky.social · 29/11/2024
⭐️Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither? Nice work spearheaded by @adesaimd.bsky.social mdpi.com/3031120
mdpi.com
Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?
Introduction: Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, despite advances in immune checkpoint inhibitors and targeted therapies. Antibody–drug c...
063
Reposted by @pgrivasmdphd.bsky.social
Vivek Subbiah, MD @viveksubbiah.bsky.social · 29/11/2024
The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial - Annals of Oncology www.annalsofoncology.org/article/S092...
annalsofoncology.org
DEFINE_ME
071
Reposted by @pgrivasmdphd.bsky.social
Matthias Guckenberger @mguckenberger.bsky.social · 26/11/2024
PEACE-1 published Radiotherapy of the prostate in metastatic pts prevents serious GU complications, in pts with low and high tumor burden How to select patients? - all ? - based on live expectancy ? - response to systemic Tx ? - prostate volume ? www.thelancet.com/journals/lan...
thelancet.com
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Combining radiotherapy with standard of care plus abiraterone improves radiographic progression-free survival and castration resistance-free survival, but not overall survival in patients with low-vol...
0116
pgrivasmdphd.bsky.social @pgrivasmdphd.bsky.social · 29/11/2024
Thanks @achoud72.bsky.social for the tips! Amazing meetings in Vienna: #PROSCA24 #BLADDR #RENALC @oncoalert.bsky.social Learning from & interacting with friends/colleagues! @fredhutch.bsky.social @erplimackmd.bsky.social @jrgralow.bsky.social @glaucomflecken.bsky.social @johngoremd.bsky.social
054
pgrivasmdphd.bsky.social @pgrivasmdphd.bsky.social · 29/11/2024
This is my 1st post in BlueSky wishing Happy Thanksgiving to everyone with health! Best wishes from Vienna! @erplimackmd.bsky.social @achoud72.bsky.social @lauracaba.bsky.social @oncoalert.bsky.social @johngoremd.bsky.social @drnataliagandur.bsky.social @fredhutch.bsky.social @tmprowell.bsky.social
0122